Malibu_rum67

#CHEERS!!! 🥂 Celebrate 🎊 Life And Live The Most Out Of It!!!

$IXHL has identified opportunities to pair synthetic cannabinoids with well-characterized active drug components to create new combination medicines for those that have chronic diseases with unmet needs. Learn more about our investigational therapy clinical trials: incannex.com/clinical-trial…

PSX-001 is an oral synthetic psilocybin currently being studied in combination with psychological support as a treatment for adults with Generalized Anxiety Disorder (GAD). $IXHL is dedicated to furthering the PSX-001 program and looks forward to our continued advancement in generalized anxiety disorder. 🔗 incannex.com/pipeline/psx-0…

$IXHL is working urgently to develop innovative therapies for patients with obstructive sleep apnea (OSA), rheumatoid arthritis (RA), and generalized anxiety disorder (GAD). Explore Incannex’s active clinical trials: incannex.com

IHL-42X has been granted Fast Track Designation by the @US_FDA as the program continues to advance. $IXHL is dedicated to furthering IHL-42X as a potential first-in-class oral therapy for obstructive #sleepapnea. 🔗 incannex.com/pipeline/ihl-4…

$IXHL is working to develop novel fixed-dose combination therapies and treatment regimens for patients with obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder. If you are a physician or patient interested in our investigational therapy #clinicaltrials, visit our site: incannex.com/clinical-trial…

Joel Latham, sat down for a BioPharma Boardroom Q&A to discuss Phase 2 momentum, FDA engagement, and building regulator-ready therapies for sleep apnea, inflammatory disease, and anxiety disorders. Read more: biopharmaboardroom.com/interaction/69…

March is National Sleep Awareness Month! Our program, IHL-42X, is an oral fixed-dose combination therapy of acetazolamide and dronabinol currently in clinical studies for the treatment of obstructive sleep apnea (OSA). Learn more: bit.ly/44C1HKg

$IXHL has reactivated its approved share repurchase program, which has been active over the past 2 trading days. This reflects the BoD's view that Incannex's market valuation doesn't reflect the strength of its balance sheet, progress, & potential. PR: bit.ly/3NPVIgH

It’s Fun 🤩 In The Philippines 🇵🇭 ❤️

$IXHL has entered into a Partnership Agreement with the @aasmfoundation, joining their Corporate Recognition Program to sponsor a Focused Projects Grant for Junior Investigators dedicated to Diagnosis, Management, & Treatment of sleep apnea. Read more: bit.ly/4lNTniZ

@PositiveXChief Thanks 😊

@malibu_rum67 Malibu, keep an eye Monday on HIMS & HIMZ stock & ETF. Big news just came out.

#CHEERS!!! 🥂 Celebrate 🎊 Life And Live The Most Out Of It!!!

@SCarnFrenchCAD I’m pretty sure they do😹

@malibu_rum67 Do they sell that in a bottle? I could use some of that on certain days 🤭

I’m So Happy And Grateful That Money 💰 Flows To Me With EASE!!!

@SCarnFrenchCAD We got to spin it to win it… Reciting it 3X a day really works for me… when you breathe positive air, it gives me positive spirit 😊

@malibu_rum67 In Vegas, my friend. The flow of money is part of the scenery there 😏

@GDoge9 It’s pleasant to see you my dear😻

@malibu_rum67 Yes Ms Beautiful Malibu Rum, that’s what we should be doing and to the max…!!! Life is Short, so don’t squander time because that’s what life is made of.

$IXHL yes it had to be done. Float too high for a penny in this market. But it will be 12 mill float after.

$IXHL 'FDA To Give Staff Bonuses For Speeding Up Drug Reviews; FDA In The Process Of Hiring More Than 1,000 New Scientists To Speed Up Drug Reviews' - Bloomberg News bloomberg.com/news/articles/…

$IXHL's CMO, Dr. Lou Barbato, discusses how our PSX-001 program's expert Clinical Advisory Board will serve as an essential driver of disciplined clinical and regulatory execution, informed decision making, and long term shareholder value. Learn more: bit.ly/4c45g1f

$IXHL's BoD brings decades of experience across clinical development, global regulatory strategy, finance, and operational leadership. That shared expertise helps strengthen long-term value for investors while supporting our mission to advance innovative therapies for patients.